Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
Kimberly-Clark (NYSE:KMB - Get Rating) had its target price reduced by analysts at Morgan Stanley from $137.00 to $132.00 in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. The brokerage currently has an "equal weight" rating on the stock. Morgan Stanley's price objective points to a potential upside of 14.51% from the company's previous close.
Several other research firms have also issued reports on KMB. Bank of America started coverage on shares of Kimberly-Clark in a research report on Wednesday, September 14th. They issued a "neutral" rating on the stock. UBS Group boosted their price target on shares of Kimberly-Clark from $136.00 to $142.00 and gave the company a "neutral" rating in a research report on Wednesday, July 27th. StockNews.com raised shares of Kimberly-Clark from a "hold" rating to a "buy" rating in a research report on Friday, July 22nd. Finally, Wells Fargo & Company lowered their price target on shares of Kimberly-Clark from $130.00 to $120.00 and set an "equal weight" rating on the stock in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, Kimberly-Clark has a consensus rating of "Hold" and a consensus price target of $129.62.Kimberly-Clark Stock Performance
KMB stock traded up $1.19 during mid-day trading on Tuesday, hitting $115.27. The company had a trading volume of 18,602 shares, compared to its average volume of 1,518,559. The firm has a market cap of $38.92 billion, a PE ratio of 21.79, a price-to-earnings-growth ratio of 3.89 and a beta of 0.38. The company has a debt-to-equity ratio of 10.37, a quick ratio of 0.47 and a current ratio of 0.79. Kimberly-Clark has a 12 month low of $111.90 and a 12 month high of $145.79. The stock's fifty day moving average price is $128.32 and its two-hundred day moving average price is $130.06.
Kimberly-Clark (NYSE:KMB - Get Rating) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $1.34 EPS for the quarter, missing the consensus estimate of $1.35 by ($0.01). The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.99 billion. Kimberly-Clark had a return on equity of 249.60% and a net margin of 8.87%. The business's revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.47 EPS. On average, analysts forecast that Kimberly-Clark will post 5.64 earnings per share for the current fiscal year. Hedge Funds Weigh In On Kimberly-Clark
A number of hedge funds and other institutional investors have recently bought and sold shares of KMB. Lynch & Associates IN boosted its stake in shares of Kimberly-Clark by 0.7% in the 3rd quarter. Lynch & Associates IN now owns 18,430 shares of the company's stock valued at $2,074,000 after purchasing an additional 124 shares in the last quarter. Symmetry Partners LLC boosted its stake in shares of Kimberly-Clark by 34.2% in the 3rd quarter. Symmetry Partners LLC now owns 18,802 shares of the company's stock valued at $2,116,000 after purchasing an additional 4,787 shares in the last quarter. Wedmont Private Capital purchased a new stake in shares of Kimberly-Clark in the 3rd quarter valued at $203,000. Coston McIsaac & Partners purchased a new stake in shares of Kimberly-Clark in the 2nd quarter valued at $3,167,000. Finally, Federated Hermes Inc. boosted its position in Kimberly-Clark by 44.6% during the 2nd quarter. Federated Hermes Inc. now owns 2,498,984 shares of the company's stock valued at $337,738,000 after buying an additional 770,620 shares during the period. Hedge funds and other institutional investors own 74.36% of the company's stock. Kimberly-Clark Company Profile (Get Rating)
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names.Featured ArticlesGet a free copy of the StockNews.com research report on Kimberly-Clark (KMB)3 Safe Earnings Plays for a Risk-Off MarketTyson Foods Takes a Lickin’ and Keeps on Tickin’ LowerSmall-Cap Catalyst Pharma Is Among Market's Best Price Performers3 Stocks Growing Their Businesses for 2023China-Based EV Maker BYD Set For Big European, Japanese Expansion
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kimberly-Clark, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kimberly-Clark wasn't on the list.
While Kimberly-Clark currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:
Kirk McDonald shares three stocks from different industries with different market caps and explains why each is a holding in his portfolio.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.